Given our findings and previous work demonstrating similar relationships between high FVIII and recurrent thromboembolism in other populations, further study using large, diverse samples of AIS patients is needed to investigate whether or not FVIII may have the potential to serve as a clinically useful biomarker for the identification of patients at increased risk for new in-hospital thrombotic events following AIS. This evidence concerns the gene F8 and Thromboembolism.